Orris

Tab Glycomet Gp 0.5 vs Tab Glycomet Gp 1 vs Tab Glycomet Gp 2 vs Tab Glycomet Gp 3 vs Tab Glycomet trio forte vs Tab Glycomet Gp 2 forte vs Tab Glycomet Gp 1 forte vs Janumet vs Galvus met vsZita-Plus GM vs Teneglyn-M-G vs Amaryl M Forte T vs Glycomet-GP D vs tab jalra m 50/500 vs Tab obimet gx4 vs tab dapabite vs tab Jalra m 50/500 vs Difference between these medicines and how decide which tablet should be given to which patient and how to decide or select the medicine and give the criteria based on hb1ac levels, ppbs or fbs levels Give some case examples with these medicines and how to titrate these medicines and dose If PPBS is very high then which type of medication is to choose and If FBS is very high then which type of medication is to choose and Which are absolute contraindications of class of drug in different conditions and reasons. Special considerations like IHD, HTN, CKD , hyperlipidemia, obesity, CVA , ascites, parkinson, liver failure , s/p CAG PTCA, insulinoma , sepsis in these conditions which type of class of medication should be selected and why and which class of medicine is contraindicated

Reading File
Reading File
This is a large diabetes-prescribing topic. It includes several fixed-dose combinations, interpretation of fasting and post-meal glucose patterns, safe titration, contraindications, and selection in major comorbidities. Individual prescribing cannot be safely based on HbA1c, FBS, or PPBS alone: age, hypoglycaemia risk, eGFR, liver status, weight, current medicines, cardiovascular status, and acute illness all change the choice. A very high glucose with weight loss, ketones, vomiting, dehydration, sepsis, or altered sensorium needs urgent clinical assessment and often insulin rather than tablet escalation.
Topic map
  1. Identify the ingredients and doses behind each listed brand.
  2. Compare drug classes: metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, pioglitazone, and others.
  3. Use HbA1c, fasting glucose, and PPBS patterns to identify whether basal or post-meal control is the main gap.
  4. Safe initiation, titration, monitoring, and when insulin is preferred.
  5. Case-based examples.
  6. Contraindications and precautions, including CKD, ASCVD/IHD or post-PTCA, stroke, obesity, hypertension, heart failure/ascites, liver failure, acute sepsis, and hypoglycaemia-prone states.
At a high level: metformin is usually the foundation if kidney function and acute clinical status permit; SGLT2 inhibitors are often favored when heart failure, CKD, or atherosclerotic cardiovascular disease is present; GLP-1 receptor agonists are often preferred for obesity or established ASCVD when feasible; sulfonylureas lower glucose effectively but increase hypoglycaemia and weight-gain risk; DPP-4 inhibitors are weight-neutral and low-hypoglycaemia options but differ in renal dosing; pioglitazone is avoided in heart failure or fluid retention. Fixed-dose brands should only be used after confirming each component is appropriate and the dose is individually justified.
Asking for Preferences

Which section should I cover in detail first?

This is a shared conversation. Sign in to Orris to start your own chat.